Terms: = Kidney tumors AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M
22 results:
1. Aggressive renal cell carcinoma with biphasic papillary and solid clear cell features harboring idh2 (R172M) mutation.
Zhao M; Xia Y; Wang W
Pathol Res Pract; 2024 Jan; 253():155090. PubMed ID: 38181579
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
Duffau H
J Neurooncol; 2023 Mar; 162(1):237-244. PubMed ID: 36913047
[TBL] [Abstract] [Full Text] [Related]
4. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
5. Resolving Enantiomers of 2-Hydroxy Acids by Nuclear Magnetic Resonance.
Lin P; Crooks DR; Linehan WM; Fan TW; Lane AN
Anal Chem; 2022 Sep; 94(36):12286-12291. PubMed ID: 36040304
[TBL] [Abstract] [Full Text] [Related]
6. Adrenal Cortical Carcinoma and Additional Rare Pathologic Findings in Multi-Organs in a Birt-Hogg-Dubé Syndrome Patient: With an Emphasis on the Molecular Characteristics of Adrenal Cortical Carcinoma.
Kim D; Murvelashvili N; Hamidi O; Jia L
Int J Surg Pathol; 2023 Aug; 31(5):689-694. PubMed ID: 35946080
[TBL] [Abstract] [Full Text] [Related]
7. An idh-independent mechanism of DNA hypermethylation upon VHL inactivation in cancer.
Artemov AV; Zhenilo S; Kaplun D; Starshin A; Sokolov A; Mazur AM; Szpotan J; Gawronski M; Modrzejewska M; Gackowski D; Prokhortchouk EB
Epigenetics; 2022 Aug; 17(8):894-905. PubMed ID: 34494499
[TBL] [Abstract] [Full Text] [Related]
8. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and kidney Cancer.
Kabra A; Bushweller J
J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329
[TBL] [Abstract] [Full Text] [Related]
9. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis.
Li X; Zhong X; Wang Y; Zeng X; Luo T; Liu Q
PLoS One; 2021; 16(5):e0250602. PubMed ID: 33939733
[TBL] [Abstract] [Full Text] [Related]
10. A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.
Wang H; Wang X; Xu L; Zhang J; Cao H
Sci Prog; 2021; 104(2):368504211010938. PubMed ID: 33878963
[TBL] [Abstract] [Full Text] [Related]
11. Dysregulation of the Sirt5/idh2 axis contributes to sunitinib resistance in human renal cancer cells.
Meng L; Chen D; Meng G; Lu L; Han C
FEBS Open Bio; 2021 Mar; 11(3):921-931. PubMed ID: 33455080
[TBL] [Abstract] [Full Text] [Related]
12. Multifocal Renal Cell Carcinomas With Somatic idh2 Mutation: Report of a Previously Undescribed Neoplasm.
Merino MJ; Ricketts CJ; Moreno V; Yang Y; Fan TWM; Lane AN; Meltzer PS; Vocke CD; Crooks DR; Linehan WM
Am J Surg Pathol; 2021 Jan; 45(1):137-142. PubMed ID: 33165095
[TBL] [Abstract] [Full Text] [Related]
13. idh-wildtype glioblastomas and grade III/IV idh-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract] [Full Text] [Related]
14. The cancer driver genes idh1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
15. Role of polycyclic aromatic hydrocarbons as a co-factor in human papillomavirus-mediated carcinogenesis.
Zhang C; Luo Y; Zhong R; Law PTY; Boon SS; Chen Z; Wong CH; Chan PKS
BMC Cancer; 2019 Feb; 19(1):138. PubMed ID: 30744599
[TBL] [Abstract] [Full Text] [Related]
16. Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system.
Popławski P; Wiśniewski JR; Rijntjes E; Richards K; Rybicka B; Köhrle J; Piekiełko-Witkowska A
PLoS One; 2017; 12(12):e0190179. PubMed ID: 29272308
[TBL] [Abstract] [Full Text] [Related]
17. Functional alteration of canine isocitrate dehydrogenase 2 (idh2) via an R174K mutation.
Kawakami S; Ochiai K; Kato Y; Michishita M; Hirama H; Obara R; Azakami D; Watanabe M; Omi T
J Vet Med Sci; 2018 Jan; 80(1):85-91. PubMed ID: 29162772
[TBL] [Abstract] [Full Text] [Related]
18. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Shim EH; Livi CB; Rakheja D; Tan J; Benson D; Parekh V; Kho EY; Ghosh AP; Kirkman R; Velu S; Dutta S; Chenna B; Rea SL; Mishur RJ; Li Q; Johnson-Pais TL; Guo L; Bae S; Wei S; Block K; Sudarshan S
Cancer Discov; 2014 Nov; 4(11):1290-8. PubMed ID: 25182153
[TBL] [Abstract] [Full Text] [Related]
19. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
Morin A; Letouzé E; Gimenez-Roqueplo AP; Favier J
Int J Cancer; 2014 Nov; 135(10):2237-48. PubMed ID: 25124653
[TBL] [Abstract] [Full Text] [Related]
20. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
[TBL] [Abstract] [Full Text] [Related]
[Next]
